1-19 of 19
John Timmerman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Five-Year Outcomes of Patients (Pts) with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Treated with Brexucabtagene Autoleucel (Brexu-cel) in ZUMA-2 Cohorts 1 and 2

Michael Wang, Andre Goy, Javier Munoz, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John Timmerman, Ian W. Flinn, David B. Miklos, John M. Pagel, Marie José Kersten, Edouard Forcade, Max S. Topp, Roch Houot, Amer Beitinjaneh, Dan Zheng, Mengru Chang, Rhine Shen, Wangshu Zhang, Rita Damico Khalid, Ioana Kloos, Patrick M. Reagan
Journal: Blood
Blood (2024) 144 (Supplement 1): 4388.
https://doi.org/10.1182/blood-2024-198018
Published: 2024
Journal Articles

Favezelimab in Combination with Pembrolizumab in Patients with Anti-PD-1-Naive Relapsed or Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

Nathalie A. Johnson, David Lavie, Peter Borchmann, Gareth P. Gregory, Alex F. Herrera, Leonard Minuk, Vladan Vucinic, Philippe Armand, Abraham Avigdor, Robin Gasiorowski, Yair Herishanu, Colm Keane, John Kuruvilla, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, John Timmerman
Journal: Blood
Blood (2023) 142 (Supplement 1): 1693.
https://doi.org/10.1182/blood-2023-182128
Published: 2023
Journal Articles

Open-Label, Randomized, Phase 3 Study of Coformulated Favezelimab and Pembrolizumab Versus Chemotherapy in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Refractory to Anti-PD-1 Therapy: Keyform-008

David Lavie, John Timmerman, Ramón García-Sanz, Won Seog Kim, Tae Min Kim, Abraham Avigdor, Daan Dierickx, Deepa Jagadeesh, Daniel L. Molin, Muhit Ozcan, Omur Gokmen Sevindik, Hayder Saeed, Yulia Sidi, Pallavi Pillai, Patricia Marinello, Alex F. Herrera
Journal: Blood
Blood (2023) 142 (Supplement 1): 3082.
https://doi.org/10.1182/blood-2023-182119
Published: 2023
Journal Articles

Intravenous IL-1 Receptor Antagonist for Prevention of Severe Immune Effector Cell-Associated Neurotoxicity Syndrome

Sunmin Park, Christopher Hannigan, Joseph M Tuscano, John Timmerman, Caspian H. Oliai
Journal: Blood
Blood (2023) 142 (Supplement 1): 4858.
https://doi.org/10.1182/blood-2023-183012
Published: 2023
Journal Articles

Updated Follow-up of a Phase 1 Trial of Bispecific CART19/20 Cells for Relapsed or Refractory Non-Hodgkin Lymphoma

Benjamin R Puliafito, Christopher M Walthers, Brenda Ji, Sanaz N Ghafouri, Jacob Naparstek, Jacqueline Trent, Jia Ming Chen, Mobina Roshandell, Caitlin Harris, Mobina Khericha, Melanie Ayala Ceja, Christy Sidhu, Thomas Schweppe, Beata Berent-Maoz, Stanley B Gosliner, Amr Almaktari, Karla Nawaly, Martin S Allen-Auerbach, Jonathan Said, Monica Mead, Sven de Vos, Patricia A. Young, Caspian H. Oliai, Gary J. Schiller, John Timmerman, Antoni Ribas, Yvonne Y Chen, Sarah M. Larson
Journal: Blood
Blood (2023) 142 (Supplement 1): 3490.
https://doi.org/10.1182/blood-2023-186636
Published: 2023
Journal Articles

Favezelimab in Combination with Pembrolizumab in Patients with Heavily Pretreated Anti-PD-1-Refractory Classical Hodgkin Lymphoma: Updated Analysis of an Open-Label Phase 1/2 Study

John Timmerman, David Lavie, Nathalie A. Johnson, Abraham Avigdor, Peter Borchmann, Charalambos Andreadis, Ali Bazargan, Gareth P. Gregory, Colm Keane, Inna Tzoran, Vladan Vucinic, Pier Luigi Zinzani, Rachel Marceau West, Pallavi Pillai, Patricia Marinello, Alex F. Herrera
Journal: Blood
Blood (2023) 142 (Supplement 1): 4440.
https://doi.org/10.1182/blood-2023-182019
Published: 2023
Journal Articles

Deliriogenic Medication Use in Older Adults Receiving CAR-T Correlates with Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

Michael J. Maranzano, Justin Cheng, John Timmerman, Patricia A. Young, Caspian H. Oliai, Herbert A. Eradat, Sven de Vos, Sarah M. Larson, Monica Mead
Journal: Blood
Blood (2023) 142 (Supplement 1): 7358.
https://doi.org/10.1182/blood-2023-182105
Published: 2023
Journal Articles

A Phase II Trial of the Combination of Obinutuzumab, Venetoclax, and Ibrutinib in Patients with Previously Untreated Follicular Lymphoma

Tamer Othman, Aaron S Rosenberg, John Timmerman, Benjamin Heyman, Haifaa Abdulhaq, Joseph M Tuscano
Journal: Blood
Blood (2022) 140 (Supplement 1): 11954–11955.
https://doi.org/10.1182/blood-2022-164905
Published: 2022
Journal Articles

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

Nathalie A. Johnson, David Lavie, Peter Borchmann, Gareth P. Gregory, Alex F. Herrera, Leonard Minuk, Vladan Vucinic, Philippe Armand, Abraham Avigdor, Robin Gasiorowski, Yair Herishanu, Colm Keane, John Kuruvilla, John Palcza, Pallavi Pillai, Akash Nahar, John Timmerman
Journal: Blood
Blood (2022) 140 (Supplement 1): 6540–6542.
https://doi.org/10.1182/blood-2022-166846
Published: 2022
Journal Articles

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment

John Timmerman, David Lavie, Nathalie A. Johnson, Abraham Avigdor, Peter Borchmann, Charalambos Andreadis, Ali Bazargan, Gareth P. Gregory, Colm Keane, Inna Tsoran-Rosenthal, Vladan Vucinic, Pier Luigi Zinzani, Rachel Marceau West, Pallavi Pillai, Akash Nahar, Alex F. Herrera
Journal: Blood
Blood (2022) 140 (Supplement 1): 768–770.
https://doi.org/10.1182/blood-2022-166670
Published: 2022
Journal Articles

Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients (Pts) with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): 2-Year Follow-up of ZUMA-1 Cohort 6

Olalekan O. Oluwole, Edouard Forcade, Javier Muñoz, Sophie de Guibert, Julie M. Vose, Nancy L. Bartlett, Yi Lin, Abhinav Deol, Peter A. McSweeney, Andre H. Goy, Marie José Kersten, Caron A. Jacobson, Umar Farooq, Monique C. Minnema, Catherine Thieblemont, John Timmerman, Patrick Stiff, Irit Avivi, Dimitrios Tzachanis, Yan Zheng, Saran Vardhanabhuti, Jenny Nater, Rhine R. Shen, Harry Miao, Jenny Kim, Tom van Meerten
Journal: Blood
Blood (2022) 140 (Supplement 1): 10399–10401.
https://doi.org/10.1182/blood-2022-156117
Published: 2022
Journal Articles

Efficacy and safety results from CheckMate 140, a phase 2 study of nivolumab for relapsed/refractory follicular lymphoma

Clinical Trials & Observations
Philippe Armand, Ann Janssens, Giuseppe Gritti, John Radford, John Timmerman, Antonio Pinto, Santiago Mercadal Vilchez, Peter Johnson, David Cunningham, John P. Leonard, Scott J. Rodig, Patricia Martín-Regueira, Anne Sumbul, Selda Samakoglu, Hao Tang, Stephen M. Ansell
Journal: Blood
Blood (2021) 137 (5): 637–645.
https://doi.org/10.1182/blood.2019004753
Published: 2021
Includes: Supplemental data
Journal Articles

The run-down immunologic neighborhood in Hodgkin lymphoma

John Timmerman
Journal: Blood
Blood (2018) 132 (8): 770–771.
https://doi.org/10.1182/blood-2018-07-857516
Published: 2018
Journal Articles

Kte-C19 (anti-CD19 CAR T Cells) Induces Complete Remissions in Patients with Refractory Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Pivotal Phase 2 Zuma-1

Sattva S. Neelapu, MD, Frederick L. Locke, MD, Nancy L. Bartlett, MD, Lazaros Lekakis, MD, David Miklos, MD PhD, Caron A. Jacobson, MD, Ira Braunschweig, MD, Olalekan Oluwole, MBBS, MPH, Tanya Siddiqi, MD, Yi Lin, MD PhD, John Timmerman, MD, Patrick J. Stiff, Jonathan Friedberg, MD, Ian Flinn, Andre Goy, MD, Mitchell Smith, Abhinav Deol, MD, Umar Farooq, MD, Peter McSweeney, MD, Javier Munoz, MD, Irit Avivi, MD, Januario E. Castro, MD, Jason R. Westin, MD MS, Julio C. Chavez, MD, Armin Ghobadi, MD, Krishna V. Komanduri, MD, Ronald Levy, MD, Eric D. Jacobsen, Patrick Reagan, MD, Adrian Bot, MD PhD, John M. Rossi, MS, Lynn Navale, MS, Yizhou Jiang, PhD, Jeff S. Aycock, BA, Meg Elias, RN, BSN, Jeff Wiezorek, MD MS, William Y. Go, MD PhD
Journal: Blood
Blood (2016) 128 (22): LBA-6.
https://doi.org/10.1182/blood.V128.22.LBA-6.LBA-6
Published: 2016
Journal Articles

Nivolumab in Patients with Relapsed or Refractory Hodgkin Lymphoma - Preliminary Safety, Efficacy and Biomarker Results of a Phase I Study

Philippe Armand, MD PhD, Stephen M. Ansell, MD PhD, Alexander M. Lesokhin, MD, Ahmad Halwani, MD, Michael M. Millenson, MD, Stephen J. Schuster, MD, John Timmerman, MD, Ivan Borrello, MD, Martin Gutierrez, MD, Emma C. Scott, MD, Deepika Cattry, MSc, CCRP, Bjoern Chapuy, MD PhD, Azra H. Ligon, PhD, Scott J. Rodig, MD PhD, Lili Zhu, MSc, Joseph F. Grosso, PhD, Su Young Kim, MD PhD, Margaret A. Shipp, MD
Journal: Blood
Blood (2014) 124 (21): 289.
https://doi.org/10.1182/blood.V124.21.289.289
Published: 2014
Journal Articles

Preliminary Results of a Phase I Study of Nivolumab (BMS-936558) in Patients with Relapsed or Refractory Lymphoid Malignancies

Alexander M. Lesokhin, MD, Stephen M. Ansell, MD PhD, Philippe Armand, MD PhD, Emma C. Scott, MD, Ahmad Halwani, MD, Martin Gutierrez, MD, Michael M. Millenson, MD, Adam D. Cohen, MD, Stephen J. Schuster, MD, Daniel Lebovic, Madhav V. Dhodapkar, MD, David Avigan, MD, Bjoern Chapuy, MD PhD, Azra H. Ligon, PhD, Scott J. Rodig, MD PhD, Deepika Cattry, MSc, CCRP, Lili Zhu, MSc, Joseph F. Grosso, PhD, Su Young Kim, MD PhD, Margaret A. Shipp, MD, Ivan Borrello, MD, John Timmerman, MD
Journal: Blood
Blood (2014) 124 (21): 291.
https://doi.org/10.1182/blood.V124.21.291.291
Published: 2014
Journal Articles

High PD-1 expression and suppressed cytokine signaling distinguish T cells infiltrating follicular lymphoma tumors from peripheral T cells

June H. Myklebust, Jonathan M. Irish, Joshua Brody, Debra K. Czerwinski, Roch Houot, Holbrook E. Kohrt, John Timmerman, Jonathan Said, Michael R. Green, Jan Delabie, Arne Kolstad, Ash A. Alizadeh, Ronald Levy
Journal: Blood
Blood (2013) 121 (8): 1367–1376.
https://doi.org/10.1182/blood-2012-04-421826
Published: 2013
Includes: Supplemental data
Journal Articles

Generation of CD8 + T cell–mediated immunity against idiotype-negative lymphoma escapees

Bindu Varghese, Adam Widman, James Do, Behnaz Taidi, Debra K. Czerwinski, John Timmerman, Shoshana Levy, Ronald Levy
Journal: Blood
Blood (2009) 114 (20): 4477–4485.
https://doi.org/10.1182/blood-2009-05-223263
Published: 2009
Journal Articles

Phase I/II Study of Ipilimumab (MDX-010), an Anti-CTLA-4 Monoclonal Antibody, in Patients with Follicular Non-Hodgkin Lymphoma.

Stephen M. Ansell, MD, PhD, Susan M. Geyer, PhD, Sara Hurvitz, Donna Fernando, Thomas M. Habermann, MD, David J. Inwards, MD, Meena Verma, Reiko Yamada, John Timmerman, MD
Journal: Blood
Blood (2006) 108 (11): 2729.
https://doi.org/10.1182/blood.V108.11.2729.2729
Published: 2006